UNCY
Unicycive Therapeutics, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Best Pharmaceutical Stocks 2026 →
Unicycive Therapeutics (UNCY) Stock: Buy, Sell, or Hold?
$3.64
-0.14 (-3.70%)
âŧ
5d:
+4.6%
30d:
-1.62%
90d:
-33.94%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (74%)
Quality Score
41/100
Position
SLIGHTLY LOW
30-Day Fair Range
$3.54 â $4.00
Position: SLIGHTLY LOW
Forward P/E & Valuation
2.5x
STRETCHED
vs 1.5x historical avg
Wall Street Target
$28.40
+680.2% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$3.33 / $3.93
Trend: Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: UNCY is fairly priced but lacks strong directional signals. At 18.1% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
Get Alerted When UNCY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$3.05
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$1.89
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 1.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: UNCY is currently trading at $3.64, which is considered slightly low relative to its 30-day fair value range of $3.54 to $4.00. From a valuation perspective, the stock is trading at a premium (Forward PE: 2.5) compared to its historical average (1.5). At these levels, the market is pricing in 18.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, UNCY is in a downtrend. Immediate support is located at $3.33, while resistance sits at $3.93. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: The stock scores a mixed 41/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $28.40 (+680.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, UNCY is in a downtrend. Immediate support is located at $3.33, while resistance sits at $3.93. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: The stock scores a mixed 41/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $28.40 (+680.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$3.54 -
$4.00
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
73.8%
Trading Range & Key Levels
30-Day Trading Range
$3.54 -
$4.00
Current vs Trading Range
SLIGHTLY LOW
Support Level
$3.33
Resistance Level
$3.93
Current Trend
Downtrend
Technical data as of
Nov 12, 2026
Quantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (41/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.7%)
- BULLISH: Trading 680.2% below Wall St target ($28.40)
- NEUTRAL: Trading at premium valuation - market expects 18.1% growth which is achievable
- WARNING: Composite score 41/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
2.51
Wall Street Target
$28.40
(+680.2%)
Valuation Premium vs History
+18.1% premium
PE vs Historical
2.5 vs 1.5
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+18.1%
(market-implied from PE analysis)
1-Year Target
$4.30
(+18%)
2-Year Target
$5.08
(+40%)
3-Year Target
$6.00
(+65%)
3-Yr Target (if PE normalizes)
(PE: 3â2)
PE COMPRESSION
$3.58
(-2%)
Earnings growth offset by PE compression
Share UNCY Analysis
Share this live UNCY analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (UNCY)
Bullish
3 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
2 msgs
24h retail stream
Last Tracked
Nov 11, 2026
Daily AI digest
AI Retail Discussion Summary:
Investors are expressing optimism on StockTwits regarding the upcoming earnings report for $UNCY.
Key Retail Themes:
earnings report
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 6:56 PM ET
Data refreshes hourly during market hours. Next update: 7:56 PM
Data refreshes hourly during market hours. Next update: 7:56 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is UNCY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RVMD
Revolution Medicines Inc |
STRONG BUY
25 analysts |
$261 | 38 SELL |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
21 analysts |
$95 | 41 HOLD |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$32 | 42 HOLD |
|
SNDX
Syndax Pharmaceuticals IâĻ |
STRONG BUY
12 analysts |
$35 | 58 HOLD |
|
ACHV
Achieve Life Sciences Inc |
STRONG BUY
12 analysts |
$14 | 56 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive UNCY Research Pages
